T. Schuetz

发表

Differentiated agonistic antibody targeting CD137 eradicates large tumors without hepatotoxicity.

Michael M. Schmidt, Nora Zizlsperger, R. Tighe, 2020, JCI insight.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

P. Kantoff, J. Schlom, L. M. Glodé, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, vector-controlled study of targeted immunotherapy in patients (pts) with hormone-refractory prostate cancer (HRPC).

P. Kantoff, L. M. Glodé, T. Schuetz, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I Trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in Patients with Prostate Cancer

R. DiPaola, D. Petrylak, H. Kaufman, 2006, Journal of Translational Medicine.

Overall survival (OS) analysis of a phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC).

P. Kantoff, J. Schlom, B. Blumenstein, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome).

S. McCandless, J. Muenzer, T. Schuetz, 2007, Molecular genetics and metabolism.

CTX-8573, an Innate-Cell Engager Targeting BCMA, is a Highly Potent Multispecific Antibody for the Treatment of Multiple Myeloma

Michael M. Schmidt, A. Oliphant, P. Bobrowicz, 2019, Blood.

Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma

A. Oliphant, P. Bobrowicz, Sara M. Haserlat, 2019, Immunology.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers

D. Grayzel, E. Collins, A. van Hecken, 2017, Front. Pharmacol..

7002 Further analysis of a Phase II randomized controlled trial (RCT) of a poxviral-based PSA targeted immunotherapy in metastatic castration-resistant prostate cancer (mCRPC)

P. Kantoff, J. Schlom, B. Blumenstein, 2009 .

Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development

W. You, S. H. Lee, T. Schuetz, 2022, Molecular cancer therapeutics.

Safety profile of therapeutic pox virus-based vaccines for cancer.

R. DiPaola, J. Marshall, J. Schlom, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.

P. Kantoff, J. Schlom, J. Gulley, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.